ES2902390T3 - Derivados de imidazol condensados sustituidos por grupos hidroxi terciarios como inhibidores de PI3K-gamma - Google Patents

Derivados de imidazol condensados sustituidos por grupos hidroxi terciarios como inhibidores de PI3K-gamma Download PDF

Info

Publication number
ES2902390T3
ES2902390T3 ES18797408T ES18797408T ES2902390T3 ES 2902390 T3 ES2902390 T3 ES 2902390T3 ES 18797408 T ES18797408 T ES 18797408T ES 18797408 T ES18797408 T ES 18797408T ES 2902390 T3 ES2902390 T3 ES 2902390T3
Authority
ES
Spain
Prior art keywords
alkyl
membered
cycloalkyl
heterocycloalkyl
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18797408T
Other languages
English (en)
Spanish (es)
Inventor
Brent Douty
Andrew W Buesking
David M Burns
Andrew P Combs
Nikoo Falahatpisheh
Ravi Kumar Jalluri
Daniel Levy
Padmaja Polam
Lixin Shao
Stacey Shepard
Artem Shvartsbart
Richard B Sparks
Eddy W Yue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Application granted granted Critical
Publication of ES2902390T3 publication Critical patent/ES2902390T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES18797408T 2017-10-18 2018-10-17 Derivados de imidazol condensados sustituidos por grupos hidroxi terciarios como inhibidores de PI3K-gamma Active ES2902390T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762574057P 2017-10-18 2017-10-18
US201762608897P 2017-12-21 2017-12-21
US201862727316P 2018-09-05 2018-09-05
PCT/US2018/056311 WO2019079469A1 (en) 2017-10-18 2018-10-17 CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA

Publications (1)

Publication Number Publication Date
ES2902390T3 true ES2902390T3 (es) 2022-03-28

Family

ID=64110207

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18797408T Active ES2902390T3 (es) 2017-10-18 2018-10-17 Derivados de imidazol condensados sustituidos por grupos hidroxi terciarios como inhibidores de PI3K-gamma

Country Status (35)

Country Link
US (4) US10738057B2 (enExample)
EP (2) EP4006034A1 (enExample)
JP (2) JP7244504B2 (enExample)
KR (2) KR102717072B1 (enExample)
CN (2) CN118063470A (enExample)
AU (3) AU2018350980C1 (enExample)
BR (1) BR112020007593A2 (enExample)
CA (1) CA3084589A1 (enExample)
CL (1) CL2020001047A1 (enExample)
CR (2) CR20200214A (enExample)
CY (1) CY1124814T1 (enExample)
EC (1) ECSP20024651A (enExample)
ES (1) ES2902390T3 (enExample)
GE (4) GEP20257716B (enExample)
HR (1) HRP20211827T1 (enExample)
HU (1) HUE056615T2 (enExample)
IL (3) IL295978B1 (enExample)
JO (1) JOP20200086A1 (enExample)
LT (1) LT3697789T (enExample)
MA (1) MA50398B1 (enExample)
MD (1) MD3697789T2 (enExample)
MX (1) MX2020003862A (enExample)
PE (1) PE20210169A1 (enExample)
PH (1) PH12020550442A1 (enExample)
PL (1) PL3697789T3 (enExample)
PT (1) PT3697789T (enExample)
RS (1) RS62818B1 (enExample)
SA (1) SA520411783B1 (enExample)
SG (1) SG11202003428VA (enExample)
SI (1) SI3697789T1 (enExample)
SM (1) SMT202100656T1 (enExample)
TW (2) TWI803525B (enExample)
UA (1) UA128085C2 (enExample)
WO (1) WO2019079469A1 (enExample)
ZA (1) ZA202201220B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3697789T1 (sl) 2017-10-18 2022-04-29 Incyte Corporation Kondenzirani imidazolni derivati, substituirani s terciarnimi hidroksi skupinami, kot zaviralci PI3K-gama
HUE060711T2 (hu) 2017-12-19 2023-04-28 Turning Point Therapeutics Inc Makrociklusos vegyületek betegségek kezelésére
TWI827583B (zh) * 2018-03-08 2024-01-01 美商英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之胺基吡嗪二醇化合物
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
JP7490631B2 (ja) 2018-07-05 2024-05-27 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピラジン誘導体
CR20250050A (es) * 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
WO2020247496A1 (en) 2019-06-04 2020-12-10 Arcus Biosciences, Inc. 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds
JP2021165246A (ja) * 2020-04-08 2021-10-14 国立大学法人 名古屋工業大学 ペンタフルオロエチル基含有アルコール類の製造方法、有機半導体材料および酵素活性阻害剤の製造中間体化合物
CN115286521B (zh) * 2022-07-11 2023-11-03 上海医药集团(本溪)北方药业有限公司 一种盐酸左沙丁胺醇的合成方法
WO2025152777A1 (zh) * 2024-01-18 2025-07-24 海创药业股份有限公司 一种制备雄激素受体靶向降解化合物及其盐的方法

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4269846A (en) 1979-10-29 1981-05-26 Usv Pharmaceutical Corporation Heterocyclic compounds useful as anti-allergy agents
US5137876A (en) 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
AU5620299A (en) 1998-08-11 2000-03-06 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0011092D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (III)
ES2225624T3 (es) 2000-06-28 2005-03-16 Smithkline Beecham Plc Procedimiento de molienda por via humeda.
IL160915A0 (en) 2001-09-19 2004-08-31 Aventis Pharma Sa Indolizines inhibiting kinase proteins
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
IL161576A0 (en) 2001-10-26 2004-09-27 Aventis Pharma Inc Benzimidazoles and analogues and their use as protein kinases inhibitors
KR20090087139A (ko) 2001-10-30 2009-08-14 노파르티스 아게 Ｆｌｔ３ 수용체 티로신 키나아제 활성의 억제제로서의 스타우로스포린 유도체
DE10207843A1 (de) 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
WO2004078943A2 (en) 2003-03-04 2004-09-16 California Institute Of Technology Alternative heterocycles for dna recognition
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
CA2534649A1 (en) 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
CA2542481A1 (en) * 2003-10-15 2005-04-28 Osi Pharmaceuticals, Inc. Imidazopyrazine tyrosine kinase inhibitors
WO2005118580A2 (en) 2004-05-12 2005-12-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Tricyclic compounds as inhibitors of the hypoxic signaling pathway
TW200610762A (en) 2004-06-10 2006-04-01 Irm Llc Compounds and compositions as protein kinase inhibitors
CN101106983A (zh) 2004-11-24 2008-01-16 诺瓦提斯公司 JAK抑制剂与至少一种Bcr-Abl、Flt-3、FAK或RAF激酶抑制剂的组合
CA2618370A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
TW200800213A (en) 2005-09-02 2008-01-01 Abbott Lab Novel imidazo based heterocycles
ATE456565T1 (de) 2006-06-22 2010-02-15 Biovitrum Ab Publ Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
US20090131481A1 (en) 2007-03-27 2009-05-21 Paratek Pharmaceuticals, Inc. Transcription Factor Modulating Compounds and Methods of Use Thereof
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
KR101580482B1 (ko) 2007-11-16 2015-12-28 인사이트 홀딩스 코포레이션 야누스 키나제 억제제로서의 ４－피라졸릴－ｎ－아릴피리미딘－２－아민 및 ４－피라졸릴－ｎ－헤테로아릴피리미딘－２－아민
EP2234486A4 (en) 2007-12-19 2011-09-14 Scripps Research Inst BENZIMIDAZOLES AND ANALOGS AS INHIBITORS OF RHO-KINASE
AP2010005308A0 (en) 2008-01-15 2010-06-30 Siga Technologies Inc Antiviral drugs for treatment of arenavirus infection
US8329697B2 (en) 2008-02-26 2012-12-11 Merck Sharp & Dohme Corp. Imidizo[1,2-A]pyrazines useful as AHCY hydrolase inhibitors
EA017218B1 (ru) 2008-03-11 2012-10-30 Инсайт Корпорейшн Производные азетидина и циклобутана как ингибиторы jak-киназ
AR071523A1 (es) 2008-04-30 2010-06-23 Merck Serono Sa Compuestos biciclicos fusionados, un proceso para su preparacion, el compuesto para ser utilizado como medicamento en el tratamiento y profilaxis de enfermedades, una composicion farmaceutica y un conjunto que comprende paquetes separados del compuesto y de un ingrediente activo del medicamento
WO2009158118A2 (en) 2008-05-30 2009-12-30 University Of Notre Dame Du Lac Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria
WO2010051245A1 (en) 2008-11-03 2010-05-06 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides
WO2010061903A1 (ja) 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
CA2753560A1 (en) 2009-02-27 2010-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatidylinositol 3-kinase
EP2419429B1 (en) * 2009-04-16 2014-03-26 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines as inhibitors of protein kinases
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
SG177384A1 (en) 2009-06-29 2012-02-28 Incyte Corp Pyrimidinones as pi3k inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
TW201130842A (en) 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
WO2011099832A2 (en) 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
PE20130038A1 (es) 2010-03-10 2013-01-28 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de jak1
WO2011123609A1 (en) 2010-03-31 2011-10-06 Glaxo Group Limited Imidazolyl-imidazoles as kinase inhibitors
JP5816678B2 (ja) 2010-04-14 2015-11-18 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ＰＩ３Ｋδ阻害剤としての縮合誘導体
EP2575866A4 (en) 2010-05-24 2013-10-16 Presidio Pharmaceuticals Inc HCV NS5A INHIBITORS
EP2627650A2 (en) 2010-05-26 2013-08-21 Merck Sharp & Dohme Corp. N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
MX2013004003A (es) 2010-10-13 2013-10-01 Millenium Pharmaceuticals Inc Heteroarilos y usos de los mismos.
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
KR20140019300A (ko) 2010-11-19 2014-02-14 인사이트 코포레이션 Ｊａｋ 억제제로서 사이클로부틸 치환된 피롤로피리딘 및 피롤로피리미딘 유도체
PE20140161A1 (es) 2010-11-30 2014-02-19 Takeda Pharmaceutical Compuesto biciclico
CA2822070C (en) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US8673905B2 (en) 2011-03-17 2014-03-18 Hoffmann-La Roche Inc. Imidazo pyrazines
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
KR102104125B1 (ko) 2011-04-21 2020-05-29 재단법인 한국파스퇴르연구소 소염 화합물
US9181214B2 (en) 2011-06-09 2015-11-10 Rhizen Pharmaceuticals Sa Bicyclic compounds as modulators of GPR-119
EA201490042A1 (ru) 2011-06-20 2014-10-30 Инсайт Корпорейшн Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
MY179332A (en) 2011-09-02 2020-11-04 Incyte Holdings Corp Heterocyclylamines as pl3k inhibitors
CN104066735B (zh) * 2012-01-10 2016-08-31 拜耳知识产权有限责任公司 作为akt激酶抑制剂的取代的咪唑并吡嗪
US9212169B2 (en) 2012-03-01 2015-12-15 Hyogo College Of Medicine Benzimidazole derivative and use thereof
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
CN104334552B (zh) 2012-05-31 2016-08-31 住友化学株式会社 稠合杂环化合物
PT2872491T (pt) 2012-07-11 2021-08-05 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
BR112015000675B1 (pt) 2012-07-13 2022-07-12 UCB Biopharma SRL Derivados de imidazopiridina como moduladores da atividade de tnf
CA2888816A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
TWI841376B (zh) 2013-03-01 2024-05-01 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
WO2014149207A2 (en) 2013-03-15 2014-09-25 Dow Agrosciences Llc Benzimidazole-based insecticidal compositions and related methods
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
US9656994B2 (en) 2013-03-22 2017-05-23 The Scripps Research Institute Substituted benzimidazoles as nociceptin receptor modulators
US9394254B2 (en) 2013-05-08 2016-07-19 The University of Denver and Regis University Antibiotic and anti-parasitic agents that modulate class II fructose 1,6-bisphosphate aldolase
SI3786162T1 (sl) 2013-05-17 2024-02-29 Incyte Holdings Corporation Bipirazolni derivati kot zaviralci JAK
MY184572A (en) 2013-07-17 2021-04-05 Otsuka Pharma Co Ltd Cyanotriazole compounds
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX373202B (es) 2014-04-08 2020-05-04 Incyte Holdings Corp Tratamiento de neoplasias malignas de linfocitos b mediante una combinacion de inhibidores de janus cinasa (jak) y fosfatidilinositol 3 cinasa (pi3k).
EP2930048A1 (en) 2014-04-10 2015-10-14 Johnson Controls Automotive Electronics SAS Head up display projecting visual information onto a screen
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
US9676770B2 (en) 2014-09-16 2017-06-13 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
ES2807785T3 (es) * 2014-10-22 2021-02-24 Bristol Myers Squibb Co Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k
ES2749679T3 (es) * 2014-10-22 2020-03-23 Bristol Myers Squibb Co Compuestos de pirrolotriazina amina sustituidos como inhibidores de PI3k
MA40933A (fr) 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
WO2016106624A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
US9968604B2 (en) * 2015-04-16 2018-05-15 Chiesi Farmaceutici S.P.A. Chromene derivatives as phoshoinositide 3-kinases inhibitors
CA2984496A1 (en) 2015-05-12 2016-11-17 Kalyra Pharmaceuticals, Inc. Bicyclic compounds
LT3371190T (lt) 2015-11-06 2022-08-10 Incyte Corporation Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai
ES2995198T3 (en) 2016-01-05 2025-02-07 Incyte Corp Pyridine compounds as pi3k-gamma inhibitors
TW201803871A (zh) * 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
CA3034802A1 (en) 2016-08-26 2018-03-01 Mitsubishi Tanabe Pharma Corporation Bicyclic nitrogenated heterocyclic compound
US20200000713A1 (en) 2017-01-20 2020-01-02 Massachusetts Institute Of Technology Injectable polymer micro-depots for controlled local drug delivery
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
JP7412328B2 (ja) 2017-07-24 2024-01-12 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
WO2019079540A1 (en) 2017-10-18 2019-04-25 Epizyme, Inc. AMINO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF EHMT2, SALTS THEREOF, AND METHODS OF SYNTHESIS THEREOF
SI3697789T1 (sl) 2017-10-18 2022-04-29 Incyte Corporation Kondenzirani imidazolni derivati, substituirani s terciarnimi hidroksi skupinami, kot zaviralci PI3K-gama
HUE060711T2 (hu) 2017-12-19 2023-04-28 Turning Point Therapeutics Inc Makrociklusos vegyületek betegségek kezelésére
EP3728199B1 (en) 2017-12-21 2025-05-14 Basf Se Pesticidal compounds
CR20200312A (es) 2017-12-21 2020-09-11 Boehringer Ingelheim Int Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)

Also Published As

Publication number Publication date
MX2020003862A (es) 2020-08-13
CN111542526A (zh) 2020-08-14
GEAP202215327A (en) 2022-10-10
JP7541594B2 (ja) 2024-08-28
EP3697789A1 (en) 2020-08-26
SI3697789T1 (sl) 2022-04-29
ZA202201220B (en) 2023-03-29
CR20210442A (es) 2021-12-20
HRP20211827T1 (hr) 2022-03-18
PE20210169A1 (es) 2021-01-29
CA3084589A1 (en) 2019-04-25
JP7244504B2 (ja) 2023-03-22
US20200385392A1 (en) 2020-12-10
CN111542526B (zh) 2024-01-09
GEAP202416013A (en) 2024-08-26
MA50398B1 (fr) 2021-10-29
US11225486B2 (en) 2022-01-18
JP2023085290A (ja) 2023-06-20
TW202340200A (zh) 2023-10-16
TWI803525B (zh) 2023-06-01
EP4006034A1 (en) 2022-06-01
GEP20257716B (en) 2025-01-27
US20190152975A1 (en) 2019-05-23
CL2020001047A1 (es) 2020-08-28
GEP20237483B (en) 2023-03-27
JP2021500340A (ja) 2021-01-07
AU2023203088A1 (en) 2023-06-15
KR20240152947A (ko) 2024-10-22
AU2018350980B2 (en) 2023-02-23
PH12020550442A1 (en) 2021-05-31
WO2019079469A1 (en) 2019-04-25
US12516065B2 (en) 2026-01-06
IL295978A (en) 2022-10-01
PT3697789T (pt) 2021-12-31
US10738057B2 (en) 2020-08-11
US11926630B2 (en) 2024-03-12
SA520411783B1 (ar) 2024-05-12
CY1124814T1 (el) 2022-11-25
AU2018350980A1 (en) 2020-04-30
IL295978B1 (en) 2023-09-01
MA50398A (fr) 2021-05-05
MD3697789T2 (ro) 2022-02-28
SG11202003428VA (en) 2020-05-28
KR102717072B1 (ko) 2024-10-15
LT3697789T (lt) 2021-12-10
TW201927788A (zh) 2019-07-16
TWI834560B (zh) 2024-03-01
US20220213107A1 (en) 2022-07-07
KR20200089264A (ko) 2020-07-24
AU2024287193A1 (en) 2025-01-23
RS62818B1 (sr) 2022-02-28
CR20200214A (es) 2020-07-25
SMT202100656T1 (it) 2022-01-10
IL273983B2 (en) 2023-02-01
JOP20200086A1 (ar) 2020-04-30
HUE056615T2 (hu) 2022-02-28
EP3697789B1 (en) 2021-09-29
PL3697789T3 (pl) 2022-02-21
IL273983B (en) 2022-10-01
US20240228498A1 (en) 2024-07-11
AU2018350980C1 (en) 2024-12-12
AU2023203088B2 (en) 2024-10-03
UA128085C2 (uk) 2024-04-03
BR112020007593A2 (pt) 2020-09-24
ECSP20024651A (es) 2020-06-30
CN118063470A (zh) 2024-05-24
IL273983A (en) 2020-05-31
IL295978B2 (en) 2024-01-01

Similar Documents

Publication Publication Date Title
ES2902390T3 (es) Derivados de imidazol condensados sustituidos por grupos hidroxi terciarios como inhibidores de PI3K-gamma
ES2910071T3 (es) Compuestos de aminopirazina diol como inhibidores de PI3K-Y
WO2020010003A1 (en) AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
WO2020102150A1 (en) Heterocyclic derivatives as pi3k inhibitors
HK40075013A (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
HK40036959B (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
HK40036959A (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
EA043981B1 (ru) ТРЕТИЧНЫЕ СПИРТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PI3K-γ
EA049371B1 (ru) ТРЕТИЧНЫЕ СПИРТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kg